Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Imiquimod 5% cream (Aldara).

Slade HB, Owens ML, Tomai MA, Miller RL.

Expert Opin Investig Drugs. 1998 Mar;7(3):437-49.

PMID:
15991984
2.

Imiquimod.

Richwald GA.

Drugs Today (Barc). 1999 Jul;35(7):497-511.

PMID:
12973395
3.

A guide to immunotherapy of genital warts: focus on interferon and imiquimod.

Czelusta AJ, Evans T, Arany I, Tyring SK.

BioDrugs. 1999 May;11(5):319-32.

PMID:
18031142
4.

Mechanism of action of imiquimod 5% cream in the treatment of anogenital warts.

Tyring SK, Arany I I, Stanley MA, Stoler MH, Tomai MA, Miller RL, Owens ML, Smith MH.

Prim Care Update Ob Gyns. 1998 Jul 1;5(4):151-152.

PMID:
10838280
6.

Percutaneous penetration of Aldara cream, 5% during the topical treatment of genital and perianal warts.

Owens ML, Bridson WE, Smith SL, Myers JA, Fox TL, Wells TM.

Prim Care Update Ob Gyns. 1998 Jul 1;5(4):151.

PMID:
10838279
7.

T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol.

Pinto RA, Arredondo SM, Bono MR, Gaggero AA, Díaz PV.

Pediatrics. 2006 May;117(5):e878-86. Epub 2006 Apr 17.

PMID:
16618789
8.

Human papillomavirus: burden of illness and treatment cost considerations.

Fox PA, Tung MY.

Am J Clin Dermatol. 2005;6(6):365-81. Review.

PMID:
16343025
9.

Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial.

Stockfleth E, Beti H, Orasan R, Grigorian F, Mescheder A, Tawfik H, Thielert C.

Br J Dermatol. 2008 Jun;158(6):1329-38. doi: 10.1111/j.1365-2133.2008.08520.x. Epub 2008 Mar 20.

PMID:
18363746
10.

Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).

Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R.

Clin Ter. 2006 Jul-Aug;157(4):377-86. Review. Retraction in: Clin Ter. 2008 May-Jun;159(3):207.

PMID:
17051976
11.

Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463.

Imbertson LM, Beaurline JM, Couture AM, Gibson SJ, Smith RM, Miller RL, Reiter MJ, Wagner TL, Tomai MA.

J Invest Dermatol. 1998 May;110(5):734-9.

12.

Immune response modification: imiquimod.

Tyring S.

Australas J Dermatol. 1998 Nov;39 Suppl 1:S11-3.

PMID:
9842095
13.

Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.

Dey R, Majumder N, Bhattacharyya Majumdar S, Bhattacharjee S, Banerjee S, Roy S, Majumdar S.

Scand J Immunol. 2007 Dec;66(6):671-83.

14.

Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential.

Stanley MA.

Clin Exp Dermatol. 2002 Oct;27(7):571-7. Review.

PMID:
12464152
15.

Immunomodulation as a treatment strategy for genital herpes: review of the evidence.

Miller RL, Tomai MA, Harrison CJ, Bernstein DI.

Int Immunopharmacol. 2002 Mar;2(4):443-51. Review.

PMID:
11962724
16.

Immunomodulatory and pharmacologic properties of imiquimod.

Sauder DN.

J Am Acad Dermatol. 2000 Jul;43(1 Pt 2):S6-11. Review.

PMID:
10861101
18.

Role of IFN-alpha/beta signaling in the prevention of genital herpes virus type 2 infection.

Svensson A, Bellner L, Magnusson M, Eriksson K.

J Reprod Immunol. 2007 Jun;74(1-2):114-23. Epub 2006 Nov 7.

PMID:
17092567
19.

[Novel vaccines against M. tuberculosis].

Okada M.

Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.

PMID:
17240920
20.

Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production.

Castellano LR, Filho DC, Argiro L, Dessein H, Prata A, Dessein A, Rodrigues V.

Hum Immunol. 2009 Jun;70(6):383-90. doi: 10.1016/j.humimm.2009.01.007. Epub 2009 Jan 20.

PMID:
19480861

Supplemental Content

Support Center